Business
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles.
About this update from Gb Sciences, Inc.
[{"type":"text","content":"\n\n\n\nGB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nGB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles\nCanada NewsWire\nLAS VEGAS, Nov. 20, 2018\n\n\n\nFirst of their kind, myrcene nanoparticles are central to a novel, time-released therapeutic for neuropathic pain\n LAS VEGAS, Nov. 20, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment of neuropathic pain. \n\n \n \n\n \n\"We have achieved a significant research milestone in the creation of the myrcene-containing nanoparticles that are at the core of our patent-pending, myrcene-based complex mixtures for the treatment of neuropathic pain,\" said Dr. Andrea Small-Howard. \"Our colleagues at the Universidad de Sevilla had to overcome serious physical and chemical challenges to stabilize the very small myrcene molecules that are prone to evaporating. USE is also creating nanoparticle versions of the other compounds in our myrcene-containing complex mixtures; however, these other terpenoids and cannabinoids should not be as challenging because they are bigger, and USE has discovered ways to stabilize small molecules, like myrcene.\"\nBack in October of 2017, GB Sciences, Inc. entered into a Contract Research Agreement with the Universidad de Sevilla to develop a time-released version of GB Sciences' proprietary, THC-free, myrcene-based chronic pain formulations, which contain a mixture of terpenoids and cannabinoids. USE researchers have created a prototype of the myrcene-containing nanoparticles, and GB and USE will begin functional testing of these formulations.\n\"We are so pleased to be working with GB Sciences on this very important project that has such potential to help people with neuropathic...